Unlocking the power of the immune system

Nectin Therapeutics is a pre‐clinical stage biopharmaceutical company developing next generation cancer immunotherapeutics. The Company has a strong pre‐clinical pipeline of several proprietary immune checkpoints inhibiting monoclonal antibodies, CAR‐T cells and antibody‐drug conjugates targeting key regulatory proteins of the prominent Nectin family of proteins. Immune checkpoint inhibitors developed by Nectin Therapeutics have the potential of becoming stand‐alone cancer immunotherapies as well as effective agents used in combination with approved, blockbuster immune‐oncological drugs in order to boost the response rate and duration.